Welcome to our dedicated page for Certara news (Ticker: CERT), a resource for investors and traders seeking the latest updates and insights on Certara stock.
Certara, Inc. (NASDAQ: CERT) delivers biosimulation solutions and model-informed drug development services that accelerate pharmaceutical innovation. This page provides comprehensive coverage of Certara's latest news, including regulatory milestones, strategic partnerships, and advancements in simulation technology.
Investors and industry professionals will find timely updates on earnings reports, product launches, and scientific developments shaping the drug development landscape. Our curated collection features press releases on regulatory submissions, technology platform enhancements, and collaborations with biopharma leaders.
Key focus areas include Certara's biosimulation software updates, regulatory science achievements, and innovations in quantitative pharmacology. Bookmark this page to stay informed about developments impacting clinical trial optimization and global drug approval processes.
Certara, Inc. recently announced the release of Pinnacle 21 Enterprise version 5.2.0, enhancing biosimulation software for validating clinical trial data. This update includes new analytics features to ensure compliance with FDA regulations, improved team collaboration tools, and enhanced security measures. The new Pinnacle 21 Data Exchange module streamlines data ingestion from external sources, promising significant time savings in clinical studies, as evidenced by a recent pilot with a major pharmaceutical client.
Certara has announced a two-year collaboration with Memorial Sloan Kettering Cancer Center (MSK) to develop a new biosimulation platform aimed at enhancing CAR T-cell therapies for multiple myeloma. The initiative will utilize de-identified clinical data from MSK to optimize dosing strategies and evaluate combination therapies. Dr. Sham Mailankody emphasized the need for improved treatments for relapsed patients. This partnership aims to accelerate innovative solutions to improve cancer therapy outcomes.
Certara, a leader in biosimulation, has appointed Rosemary Crane to its Board of Directors, effective July 21, 2022. This addition increases the board to eleven members. CEO William F. Feehery expressed enthusiasm about Crane's experience in executive leadership and commercialization, which is expected to significantly benefit the company’s growth in the biopharmaceutical sector. Crane brings over 35 years of industry experience, having held leadership positions at several major pharmaceutical companies, including a successful IPO at Epocrates.
Certara, a leader in biosimulation, has appointed Eran Broshy to its Board of Directors, effective July 11, 2022, expanding the board to ten members. Broshy brings over 35 years of experience in healthcare, previously serving as CEO and chairman of inVentiv Health, now part of Syneos Health. His expertise in high-growth healthcare businesses is expected to enhance Certara's strategic direction in drug development. Certara's biosimulation software is used by over 2,000 clients globally, aiming to improve patient outcomes.
Certara, Inc. (Nasdaq: CERT) will release its Q2 2022 financial results on August 9, 2022, after market close. A conference call with management is scheduled for 5:00 p.m. ET to discuss these results. Interested investors must register online. An archived webcast will be available on the Certara website.
Certara has launched the Simcyp Discovery Simulator, designed for small molecule drug discovery and translational research. This advanced software enhances early-stage development decisions using physiologically-based pharmacokinetic (PBPK) modeling, aimed at reducing the high failure rate of preclinical drugs. The simulator includes PBPK models for various species and supports early formulation simulations and drug-drug interaction predictions. Certara's commitment to improving drug development processes is underscored by their technological advancements.
Certara announces enhancements to its biosimulation tools, including new versions of its Immunogenicity (IG), Immuno-oncology (IO), and Vaccine Simulators. These innovations aim to improve drug development predictability across various therapeutic areas. Key advancements in the IG Simulator (Version 5.0) allow for more comprehensive evaluation of biologics, while the IO Simulator (Version 4.0) facilitates optimal cancer therapy combinations. Additionally, the Vaccine Simulator addresses dosing strategies for diverse patient populations, contributing to the development of next-generation mRNA vaccines.
Certara, Inc. (Nasdaq: CERT) reported its Q1 2022 financial results, showcasing a 22% revenue growth to $81.6 million compared to Q1 2021. Net income rose to $2.2 million, reflecting a 110% increase. Adjusted EBITDA was $27.7 million, up 16% year-over-year. The company anticipates FY 2022 revenue guidance between $350 - $360 million and adjusted diluted EPS of $0.48 - $0.53. CEO William F. Feehery emphasized the strong demand for their technology-driven services despite some COVID-related delays.
Certara, Inc. (Nasdaq: CERT), a leader in biosimulation, announced participation in several upcoming investor conferences. Key events include the Bank of America 2022 Healthcare Conference on May 10, Citi’s Biopharma Virtual Co-Panel Day on May 18, Jefferies Healthcare Conference from June 8-10, and William Blair’s Annual Growth Stock Conference on June 9. Live webcasts will be available on Certara's investor relations website, with replays accessible for 90 days. Certara specializes in accelerating drug discovery using proprietary biosimulation software.
Certara, Inc. (Nasdaq: CERT) will announce its financial results for Q1 2022 on May 5, 2022, after market close. A conference call to discuss these results will take place at 5:00 p.m. ET. Interested investors can participate by calling specific numbers for domestic and international audiences. Certara utilizes proprietary biosimulation software to enhance drug discovery and development, serving over 2,000 clients worldwide.
